Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice

Molecular Therapy Nucleic Acids

Volumn 5, Issue , 2016, Pages e317-

  Yu, Rosie Z ^a   Graham, Mark J ^a   Post, Noah ^a   Riney, Stan ^a   Zanardi, Thomas ^a   Hall, Shannon ^a   Burkey, Jennifer ^a   Shemesh, Colby S ^a   Prakash, Thazha P ^a   Seth, Punit P ^a   Swayze, Eric E ^a   Geary, Richard S ^a   Wang, Yanfeng ^a   Henry, Scott ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

antisense oligonucleotide; disposition; mice; pharmacokinetics

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN A; ISIS 681257; LIPOPROTEIN A; MESSENGER RNA; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; FEMALE; IN VIVO STUDY; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMA CLEARANCE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICOKINETICS; TRANSGENIC MOUSE; URINARY EXCRETION;

EID: 84965106860     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2016.26     Document Type: Article

References (26)

1. Bennett, CF and Swayze, EE (2010). RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50: 259-293.
2. Crooke, ST (2004). Antisense strategies. Curr Mol Med 4: 465-487.
3. Manoharan, M (1999). 2′-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochim Biophys Acta 1489: 117-130.
4. McKay, RA, Miraglia, LJ, Cummins, LL, Owens, SR, Sasmor, H and Dean, NM (1999). Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J Biol Chem 274: 1715-1722.
5. Henry, SP and Danis, RP (2001). Potential therapeutic application of antisense oligonucleotides in the treatment of ocular diseases. Expert Opinion on Pharmacotherapy 2: 277-291.
6. Yu, RZ, Geary, RS, Kim, TW and Levin, AA (2007). Mouse and monkey toxicokinetics of a second generation antisense oligonucleotide (ASO) targeting human ApoB-100, following chronic treatment for up to 1 year. Annul Meeting of American Association of Pharmaceutical Scientists, vol. Abstract #: T2492: San Diego, CA.
7. Geary, RS (2009). Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 5: 381-391.
8. Chi, KN, Eisenhauer, E, Fazli, L, Jones, EC, Goldenberg, SL, Powers, J et al. (2005). A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97: 1287-1296.
9. Graham, MJ, Lee, RG, Bell, TA 3rd, Fu, W, Mullick, AE, Alexander, VJ et al. (2013). Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 112: 1479-1490.
10. Kastelein, JJ, Wedel, MK, Baker, BF, Su, J, Bradley, JD, Yu, RZ et al. (2006). Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by shorttermadministration of an antisense inhibitor of apolipoprotein B. Circulation 114: 1729-1735.
11. Geary, RS, Khatsenko, O, Bunker, K, Crooke, R, Moore, M, Burckin, T et al. (2001). Absolute bioavailability of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J Pharmacol Exp Ther 296: 898-904.
12. Geary, RS, Yu, RZ, Watanabe, T, Henry, SP, Hardee, GE, Chappell, A et al. (2003). Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 31: 1419-1428.
13. Geary, RS, Norris, D, Yu, R and Bennett, CF (2015). Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87: 46-51.
14. Yu, RZ, Kim, TW, Hong, A, Watanabe, TA, Gaus, HJ and Geary, RS (2007). Cross-speciespharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 35: 460-468.
15. Yu, RZ, Grundy, JS and Geary, RS (2013). Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol 9: 169-182.
16. Akinc, A, Querbes, W, De, S, Qin, J, Frank-Kamenetsky, M, Jayaprakash, KN et al. (2010). Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-basedmechanisms. Mol Ther 18: 1357-1364.
17. Kanasty, R, Dorkin, JR, Vegas, A and Anderson, D (2013). Delivery materials for siRNA therapeutics. Nat Mater 12: 967-977.
18. Prakash, TP, Graham, MJ, Yu, J, Carty, R, Low, A, Chappell, A et al. (2014). Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetylgalactosamine improves potency 10-fold in mice. Nucleic Acids Res 42: 8796-8807.
19. Erqou, S, Kaptoge, S, Perry, PL, Di Angelantonio, E, Thompson, A, White, IR, et al. (2009). Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302: 412-423.
20. Erqou, S, Thompson, A, Di Angelantonio, E, Saleheen, D, Kaptoge, S, Marcovina, S et al. (2010). Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 55: 2160-2167.
21. Frazer, KA, Narla, G, Zhang, JL and Rubin, EM (1995). The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice. Nat Genet 9: 424-431.
22. Sewell, KL, Geary, RS, Baker, BF, Glover, JM, Mant, TG, Yu, RZ et al. (2002). Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 303: 1334-1343.
23. Davies, B and Morris, T (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093-1095.
24. Geary, RS, Wancewicz, E, Matson, J, Pearce, M, Siwkowski, A, Swayze, E et al. (2009). Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2′-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN. Biochem Pharmacol 78: 284-291.
25. Yu, RZ, Baker, B, Chappell, A, Geary, RS, Cheung, E and Levin, AA (2002). Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem 304: 19-25.
26. Watanabe, TA, Geary, RS and Levin, AA (2006). Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides 16: 169-180.